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Introduction 
 
Past attempts at understanding the biological basis of chronic lymphocytic leukaemia (CLL) 
have mainly focussed on genomic alterations and gene expression at the mRNA level. 
However, the molecular basis of CLL variability remains incompletely understood. We 
speculate that this is because the clinical phenotype is ultimately determined by gene 
expression at the protein level. However, to-date there are no large-scale studies which have 
investigated the human CLL proteome. We have therefore embarked on a large-scale 
proteomic study of CLL trial samples (~350) for which whole genome sequencing (WGS) 
data will be available through the Genomics England Ltd (GEL) CLL Pilot Project in an 
attempt to bridging the gap in our understanding between genotype and clinical phenotype. 
 
Recently developed mass spectrometric (MS) technologies provide an opportunity to 
develop new diagnostic, prognostic and predictive biomarkers. SWATH (Sequential 
Windowed Acquisition of all THeoretical fragments) generates a mass spectral library of 
fragment ions from all detectable peptide precursors. The composite MS/MS spectra are 
deconvoluted by alignment with a high quality and comprehensive tissue specific database, 
whereupon patient samples can be stratified based on the quantitative expression profile of 
thousands of proteins. 
 
We have already generated a CLL-specific database containing mass spectral information 
for over 7500 proteins found in blood CLL cells. Here we report the biological and technical 
variability of SWATH data acquired from patient samples and the development of 
bioinformatic tools to remove batch effects and determine the number of sample 
preparations and technical replicates required for each patient sample to achieve high 
statistical power for a large-scale proteogenomic study. 
 
Methods 
 
Protein lysates from 20 cryopreserved CLL PBMC samples (10 IGHV-unmutated and 10 
IGHV-mutated) were prepared and delivered into a TripleTOF 6600 mass spectrometer 
(SCIEX) via an Eksigent nanoLC 415 system (SCIEX). Data independent acquisition was 
performed using 100 SWATH windows of 5 Da effective isolation width to cover a mass 
range of 350-1250 m/z. Spectra were aligned using PeakView (SCIEX) against our in-house 
CLL-specific database (7773 protein entries). Peak areas from peptides with >99% 
confidence and <1% global false discovery rate were used for protein identification and 
quantification. A quadratic linear model was used to predict standard deviations at different 
mean protein levels. This was utilized in a statistical power analysis, to calculate the number 
of patients needed to reach high statistical power, with a 2 fold change in mean protein 
expression levels. 
 
To assess the SWATH data for sample preparation and MS run batch effects, 6 
cryopreserved CLL PBMC samples (3 IGHV-unmutated and 3 IGHV-mutated) were 
prepared for SWATH-MS on three separate days, with all prepared samples run on three 
independent MS runs. This produced a dataset of 54 samples. Variability in and between 
possible batches were assessed using cluster, PCA, coefficient of variation and ANOVA 
analyses. Several batch correction algorithms were evaluated for their ability to remove 
batches. 
 
Results 
 
We have generated a CLL-specific protein database containing 7773 proteins. This covers 
over 50% of all human UniProtKB/SwissProt entries which have evidence at the protein level 
(n=14,709), and includes over 87% of the proteins involved in BCR signalling (MetaCore 
database, Thomson Reuters). Our SWATH-MS data show that biological variation between 
CLL samples is high, and therefore analysis should be conducted using a large number of 
trial samples in order to detect differentially expressed proteins with high statistical power. 
However, technical reproducibility between sample preparations and mass spectrometry 
runs was shown to be high, with coefficient of variation (CV) of 3.26% and 2.43% 
respectively. In addition, batch effects were successfully corrected using Combat, from the 
sva package, in R. 
 
Conclusions 
 
Our results show that number of biological replicates should be prioritised over technical 
replicates when screening protein expression by SWATH-MS in CLL samples. We are now 
using these findings and batch correction methods to screen the proteomes of trial samples 
by SWATH-MS and, in combination with advanced computational biology techniques, will 
relate protein expression to whole genome sequencing data. In doing so, we hope to identify 
novel drug targets and predictive biomarkers of disease progression and treatment 
response. 
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